The High Authority for Health (HAS) validated on Thursday the vaccine developed by the Moderna group against the main virus causing bronchiolitis so that it has its place among other vaccines to protect seniors against this respiratory syncytial virus ( VRS).
In its recommendation, the HAS considers that “the mRESVIA vaccine can be used, in the same way as other RSV vaccines, as part of the current vaccination strategy against RSV infections in adults, namely in people aged 75 and over and in people aged 65 and over with chronic respiratory or cardiac pathologies”.
The HAS does not comment, at this stage, on the relevance and necessity of repeating vaccination after a first injection. In order to simplify the vaccination process, she believes that “the mRESVIA vaccine can be administered concomitantly with the flu and Covid-19 vaccines”.
HAS recommends quickly conducting studies to evaluate the effectiveness and real-life impact of the mRESVIA vaccine on hospitalizations due to RSV and to evaluate its effectiveness in people aged 80 and over and in immunocompromised people.
An alternative to the other two options
Two other vaccines against RSV (Arexvy from the GSK laboratory and Abrysvo from the Pfizer laboratory) can be used as part of this vaccination strategy for seniors.
The mRESVIA vaccine is a messenger RNA vaccine from Moderna which targets people over 60 years of age and which received European marketing authorization (AMM) in August 2024.
Health
